Ampicillin and Sulbactam for Injection

Published Online: Wednesday, February 1, 2006

American Pharmaceutical Partners (Schaumburg, Ill) recently received FDA approval for its abbreviated new drug application for Ampicillin and Sulbactam for Injection. The product is the generic equivalent of Pfizer Inc's Unasyn. Ampicillin and Sulbactam is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium. The product is indicated for the treatment of several skin and skin structure, intra-abdominal, and gynecologic infections due to susceptible strains of microorganisms. Administered intravenously or intramuscularly, Ampicillin and Sulbactam for Injection is available in 1.5-and 3-g single-dose vials. The product is preservative-free, and each vial will include a bar code and latex-free vial stopper. For more information, visit

Latest Articles
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Latest Issues